Construction of a Recombinant Phage-vaccine Capable of Reducing the Growth Rate of an Established LL2 Tumor Model.
暂无分享,去创建一个
H. Modjtahedi | E. Sadroddiny | M. Rajabibazl | S. Khalili | M. Rasaee | Majid Asadi-Ghalehni | M. Khosravani | N. Namvar Asl
[1] H. Modjtahedi,et al. A novel recombinant anti‐epidermal growth factor receptor peptide vaccine capable of active immunization and reduction of tumor volume in a mouse model , 2017, Microbiology and immunology.
[2] Joseph F. Murphy,et al. Immunotherapy of cancers comes of age , 2017, Expert review of clinical immunology.
[3] S. Khalili,et al. Structural analyses of the interactions between the thyme active ingredients and human serum albumin , 2017 .
[4] I. Rasooli,et al. In silico design of an immunogen against Acinetobacter baumannii based on a novel model for native structure of Outer membrane protein A. , 2017, Microbial pathogenesis.
[5] A. Jahangiri,et al. Structural pierce into molecular mechanism underlying Clostridium perfringens Epsilon toxin function , 2017, Toxicon : official journal of the International Society on Toxinology.
[6] S. Khalili,et al. 3D structure of DKK1 indicates its involvement in both canonical and non-canonical Wnt pathways , 2017, Molecular Biology.
[7] B. Baradaran,et al. Phage display as a promising approach for vaccine development , 2016, Journal of Biomedical Science.
[8] S. Khalili,et al. ILP-2 modeling and virtual screening of an FDA-approved library:a possible anticancer therapy. , 2016, Turkish journal of medical sciences.
[9] A. Pourfathollah,et al. Key role of Dkk3 protein in inhibition of cancer cell proliferation: An in silico identification. , 2016, Journal of theoretical biology.
[10] M. R. Bazl,et al. In Silico and in vitro Evaluation of a Recombinant Fusion Peptide as a Novel Candidate Vaccine for EGFR-positive Tumors , 2016 .
[11] A. Jahangiri,et al. In silico analyses of Wilms׳ tumor protein to designing a novel multi-epitope DNA vaccine against cancer. , 2015, Journal of theoretical biology.
[12] S. Khalili,et al. Kremen is beyond a subsidiary co-receptor of Wnt signaling: an in silico validation , 2015 .
[13] M. Rasaee,et al. Cancer immunotherapy by a recombinant phage vaccine displaying EGFR mimotope: an in vivo study , 2015, Immunopharmacology and immunotoxicology.
[14] I. Rasooli,et al. Functional Exposed Amino Acids of BauA as Potential Immunogen Against Acinetobacter baumannii , 2015, Acta biotheoretica.
[15] H. Modjtahedi,et al. Triple tandem mimotope peptide of Epidermal Growth Factor Receptor displaying on the surface of M13 phage induces anti-tumor response in mice tumor model , 2014 .
[16] A. Jahangiri,et al. Computational vaccinology and epitope vaccine design by immunoinformatics. , 2014, Acta microbiologica et immunologica Hungarica.
[17] H. Modjtahedi,et al. Epitope mapping of epidermal growth factor receptor (EGFR) monoclonal antibody and induction of growth-inhibitory polyclonal antibodies by vaccination with EGFR mimotope , 2014, Immunopharmacology and immunotoxicology.
[18] M. Collins,et al. DNA fusion vaccine designs to induce tumor‐lytic CD8+ T‐cell attack via the immunodominant cysteine‐containing epitope of NY‐ESO 1 , 2013, International journal of cancer.
[19] S. Farajnia,et al. EGFR antisense oligonucleotides encapsulated with nanoparticles decrease EGFR, MAPK1 and STAT5 expression in a human colon cancer cell line. , 2013, Asian Pacific journal of cancer prevention : APJCP.
[20] S. Zappavigna,et al. Optimizing treatment of metastatic colorectal cancer patients with anti-EGFR antibodies: overcoming the mechanisms of cancer cell resistance , 2013, Expert opinion on biological therapy.
[21] T. Gajewski,et al. Cancer immunotherapy , 2012, Molecular oncology.
[22] Fengyu,et al. Inhibition of tumor angiogenesis in lung cancer by T4 phage surface displaying mVEGFR2 vaccine. , 2011, Vaccine.
[23] F. Yu,et al. Antitumor activity of endogenous mFlt4 displayed on a T4 phage nanoparticle surface , 2009, Acta Pharmacologica Sinica.
[24] K. Wiesmüller,et al. Mimotope vaccines for cancer immunotherapy. , 2007, Vaccine.
[25] A. Ullrich,et al. Active antimetastatic immunotherapy in Lewis lung carcinoma with self EGFR extracellular domain protein in VSSP adjuvant , 2006, International journal of cancer.
[26] F. Liu,et al. Immunogene Therapy of Tumors with Vaccine Based on Xenogeneic Epidermal Growth Factor Receptor1 , 2003, The Journal of Immunology.
[27] J. Cherrington,et al. Small molecule tyrosine kinase inhibitors: clinical development of anticancer agents , 2003, Expert opinion on investigational drugs.
[28] Wei Zhou,et al. Phage display particles expressing tumor‐specific antigens induce preventive and therapeutic anti‐tumor immunity in murine p815 model , 2002, International journal of cancer.
[29] R. Jorissen,et al. Characterization of a comparative model of the extracellular domain of the epidermal growth factor receptor , 2008, Protein science : a publication of the Protein Society.
[30] J. Woodburn,et al. The epidermal growth factor receptor and its inhibition in cancer therapy. , 1999, Pharmacology & therapeutics.
[31] H. Modjtahedi,et al. Anti‐EGFR monoclonal antibodies which act as EGF, TGFα, HB‐EGF and BTC antagonists block the binding of epiregulin to EGFR‐expressing tumours , 1998, International journal of cancer.
[32] D. Engelman,et al. Two EGF molecules contribute additively to stabilization of the EGFR dimer , 1997, The EMBO journal.
[33] A. Ullrich,et al. Noncontiguous regions in the extracellular domain of EGF receptor define ligand-binding specificity. , 1991, Cell regulation.
[34] G. P. Smith,et al. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. , 1985, Science.
[35] D. Duś,et al. LL2 cell line derived from transplantable murine Lewis lung carcinoma--maintenance in vitro and growth characteristics. , 1985, Archivum immunologiae et therapiae experimentalis.